An Oxidative Glial Profile as a Predictor of Disability and Cognitive Decline in Primary Progressive Multiple Sclerosis - Top-Institutions - MDSpire

An Oxidative Glial Profile as a Predictor of Disability and Cognitive Decline in Primary Progressive Multiple Sclerosis

  • By

  • Albert Miguela

  • Joana Maria Huertas-Pons

  • Clàudia Coll-Martinez

  • Ariadna Gifreu-Fraixinó

  • Judit Salavedra-Pont

  • Manuel Comabella

  • Luisa María Villar

  • Jordi Gich

  • Gary Álvarez-Bravo

  • Lluís Ramió-Torrentà

  • Ana Quiroga-Varela

  • April 27, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Neurological Disorders and Stroke (NINDS), NIH
    National Institute of Neurological Disorders and Stroke (NINDS), NIH

    Bethesda, MD

    Key Differentiators

    • Neurology
    • Neuroimmunology
    • Multiple Sclerosis Research

  • #2

    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Neurology
    • Multiple Sclerosis
    • Neuroimmunology

  • #3

    Department of Neurology, University of California, San Francisco (UCSF)
    Department of Neurology, University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Multiple Sclerosis
    • Neuroimmunology

  • #4

    Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School
    Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School

    Boston, MA

    Key Differentiators

    • Neurology
    • Multiple Sclerosis
    • Neuroimmunology

  • #5

    Department of Neurology, University of Oxford
    Department of Neurology, University of Oxford

    Oxford, Oxfordshire

    Key Differentiators

    • Neurology
    • Multiple Sclerosis
    • Neuroimmunology

Original Source(s)

An Oxidative Glial Profile as a Predictor of Disability and Cognitive Decline in Primary Progressive Multiple Sclerosis

  • by Albert Miguela, Joana Maria Huertas-Pons, Clàudia Coll-Martinez, Ariadna Gifreu-Fraixinó, Judit Salavedra-Pont, Manuel Comabella, Luisa María Villar, Jordi Gich, Gary Álvarez-Bravo, Lluís Ramió-Torrentà, Ana Quiroga-Varela

  • April 27, 2026

Related Content

Stem cell-derived extracellular vesicles as immunomodulatory agents: targeting pathological crosstalk in systemic lupus erythematosus and multiple sclerosis

From inflammation to neurodegeneration: an exploratory pilot study of a diagnostic framework for progression in MS

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis who are starting BRUMVI to track outcomes, safety, and patient experience over time in a real-world setting.

  • by

  • March 4, 2026

  • 2 min